Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05956626 · ClinicalTrials.gov registry record · Phase 2
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
A Phase 2 study of Stargardt Disease, sponsored by Ocugen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 14
- Study locations
NCT05956626 is a Phase 2 study of Stargardt Disease that is actively recruiting participants, run by Ocugen. The registered enrollment target is 51 participants, below the 88-participant average among 16 other Stargardt Disease trials with a reported enrollment target (42% lower). The trial reports 14 study locations across 10 states.
The verdict
NCT05956626, a Phase 2 study of Stargardt Disease, is actively recruiting participants, sponsored by Ocugen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 14
- Study locations
Study Summary
Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subjects). Phase 1 is complete and closed for enrollment. It was a multicenter, open-label, dose ranging/dose escalation study that enrolled 9 subjects.
Conditions Studied
Interventions
- DRUG OCU410ST
Study Locations (14)
Florida
- Vitreo Retinal Associates, P.A. - Gainesville
- Bascom Palmer Eye Institute - Miami
- Advanced Research, LLC - Pompano Beach
Texas
- Retina Consultants of Texas - Bellaire
- Retina Foundation of the Southwest - Dallas
- Valley Retina Institute - McAllen
Arizona
- Associated Retina Consultants - Phoenix
California
- Retinal Consultants Medical Group - Sacramento
Indiana
- Retina Partners Midwest, P.C. - Carmel
Massachusetts
- Boston Children's Hospital - Boston
Mississippi
- Mississippi Retina Associates - Jackson
Missouri
- The Retina Institute - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2023-08-25 |
| Est. Completion | 2026-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05956626
The ClinicalTrials.gov registry entry for NCT05956626 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 16 other Stargardt Disease trials with a reported enrollment target (42% lower). The listed sponsor is Ocugen, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stargardt Disease appearing as the primary indexed condition, and to 1 intervention - of which OCU410ST is the first listed.
NCT05956626 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Florida, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT05956626 about?
NCT05956626 is a clinical study titled "A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease". Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subjects). Phase 1 is co...
What is the current status of trial NCT05956626?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2023-08-25. Estimated completion is 2026-09-28.
What conditions does trial NCT05956626 study?
This clinical trial studies the following conditions: Stargardt Disease.
What interventions are being tested in trial NCT05956626?
The interventions under investigation include: OCU410ST (DRUG).
Who is sponsoring clinical trial NCT05956626?
This trial is sponsored by Ocugen, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05956626 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
ACTIVE NOT RECRUITING · Phase 2
-
Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
COMPLETED · Phase 2
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
RECRUITING
-
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.